{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-017593","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2023-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.944408+00:00","generated_at":"2026-06-08T22:42:49.590441+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Xilio reports XTX202 Phase 1/2 data: 50% disease control at ≥2.8 mg/kg, no vascular leak syndrome","bullets":["62 patients dosed; 42 evaluable for activity: 31% disease control rate (13 SD ≥9 wks) across all doses, 50% at ≥2.8 mg/kg (3/6).","No signs/symptoms of vascular leak syndrome; TRAEs primarily Grade 1-2; no discontinuations due to TRAE.","Two patients on treatment >1 year (MSS CRC and RCC); dose-dependent PK with ~15% activated drug in tumor vs <1% in plasma.","Plan to evaluate XTX202 at 4.0 mg/kg in Phase 2 for melanoma and RCC; initial data expected Q2 2024.","Milestones subject to additional capital: XTX101 combo Phase 2 start Q3 2024, XTX301 data H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-017593","json":"https://secwatch.observer/filing/0001558370-23-017593.json","markdown":"https://secwatch.observer/filing/0001558370-23-017593.md","text":"https://secwatch.observer/filing/0001558370-23-017593.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023017593/0001558370-23-017593-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023017593/xlo-20231103x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T22:42:49.590441+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}